Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies

被引:31
作者
Zhang, Yun [1 ]
Liang, Mingming [1 ]
Sun, Chenyu [2 ]
Song, Evelyn J. [3 ]
Cheng, Ce [4 ]
Shi, Tingting [1 ]
Min, Min [1 ]
Sun, Yehuan [1 ,5 ]
机构
[1] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China
[2] AMITA Hlth St Joseph Hosp Chicago, 2900 N Lake Shore Dr, Chicago, IL 60657 USA
[3] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[4] Cape Fear Valley Med Ctr, 1638 Owen Dr, Fayetteville, NC 28304 USA
[5] Anhui Med Univ, Ctr Evidence Based Practice, Hefei 230032, Anhui, Peoples R China
关键词
Proton pump inhibitors; Dementia; Meta-analysis; Risk; ALZHEIMERS-DISEASE; VITAMIN-B-12; PERFORMANCE; PREVALENCE; OMEPRAZOLE; DIAGNOSIS;
D O I
10.1007/s00228-019-02753-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose The aim of this study was to explore the relationship between proton pump inhibitors use and the risk of dementia. Methods A comprehensive literature search was conducted in English and Chinese databases from origination to December 2018. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated with a random-effects model. Subgroup analyses and sensitivity analyses were also conducted. Cochran's Q test and the I-2 statistic were used to evaluate the heterogeneity. Publication bias was assessed by Begg's test and Egger's test. Results Six studies were included, which contained a total of 166,146 participants. The overall result demonstrated a significant increase in dementia risk with proton pump inhibitors use (HR = 1.29, 95% CI = 1.12-1.49). In subgroup analyses, a significant association was detected between proton pump inhibitors use and the risk of dementia in Europe (HR = 1.46, 95% CI = 1.23-1.73) and among participants aged >= 65 years (HR = 1.39, 95% CI = 1.17-1.65). For the factor follow-up time >= 5 years, the pooled HR was 1.28 (95% CI = 1.12-1.46), demonstrating a 1.28-fold increase in the risk of dementia among proton pump inhibitors users. In the case of regional impact, participants from Europe showed an overall pooled HR estimate of 1.46 (95% CI = 1.23-1.73). There was no evidence of publication bias. Conclusions The overall result of this meta-analysis supports the hypothesis that proton pump inhibitors increase the risk of dementia. Furthermore, high-quality cohort studies are needed to confirm these findings.
引用
收藏
页码:139 / 147
页数:9
相关论文
共 51 条
[1]  
[Anonymous], LOOM DEM EP AS
[2]  
[Anonymous], 2018, Dementia
[3]  
[Anonymous], CHINESE GEN PRACTICE
[4]   The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production [J].
Badiola, Nahuai ;
Alcalde, Victor ;
Pujol, Albert ;
Muenter, Lisa-Marie ;
Multhaup, Gerd ;
Lleo, Alberto ;
Coma, Mireia ;
Soler-Lopez, Montserrat ;
Aloy, Patrick .
PLOS ONE, 2013, 8 (03)
[5]   Prevalence and Associations of the Use of Proton-Pump Inhibitors in Nursing Homes: A Cross-Sectional Study [J].
Barreto, Philipe de Souto ;
Lapeyre-Mestre, Maryse ;
Mathieu, Celine ;
Piau, Christine ;
Bouget, Catherine ;
Cayla, Franoise ;
Vellas, Bruno ;
Rolland, Yves .
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2013, 14 (04) :265-269
[6]   OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].
BEGG, CB ;
MAZUMDAR, M .
BIOMETRICS, 1994, 50 (04) :1088-1101
[7]   Risk of Incident Dementia in Drug-Untreated Arterial Hypertension: A Population-Based Study [J].
Bermejo-Pareja, Felix ;
Benito-Leon, Julian ;
Louis, Elan D. ;
Trincado, Rocio ;
Carro, Eva ;
Villarejo, Alberto ;
Gomez de la Camara, Agustin .
JOURNAL OF ALZHEIMERS DISEASE, 2010, 22 (03) :949-958
[8]   Risk factors for dementia diagnosis in German primary care practices [J].
Booker, Anke ;
Jacob, Louis E. C. ;
Rapp, Michael ;
Bohlken, Jens ;
Kostev, Karel .
INTERNATIONAL PSYCHOGERIATRICS, 2016, 28 (07) :1059-1065
[9]   Forecasting the global burden of Alzheimer's disease [J].
Brookmeyer, Ron ;
Johnson, Elizabeth ;
Ziegler-Graham, Kathryn ;
Arrighi, H. Michael .
ALZHEIMERS & DEMENTIA, 2007, 3 (03) :186-191
[10]   Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography [J].
Cheng, FC ;
Ho, YF ;
Hung, LC ;
Chen, CF ;
Tsai, TH .
JOURNAL OF CHROMATOGRAPHY A, 2002, 949 (1-2) :35-42